- Home
- REKR vs CABA Comparison
REKR vs CABA Comparison
Compare REKR & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REKR
- CABA
- Stock Information
- Founded
- REKR 2017
- CABA 2017
- Country
- REKR United States
- CABA United States
- Employees
- REKR N/A
- CABA N/A
- Industry
- REKR Telecommunications Equipment
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REKR Telecommunications
- CABA Health Care
- Exchange
- REKR Nasdaq
- CABA Nasdaq
- Market Cap
- REKR 115.1M
- CABA 118.8M
- IPO Year
- REKR N/A
- CABA 2019
- Fundamental
- Price
- REKR $0.87
- CABA $1.39
- Analyst Decision
- REKR
- CABA Strong Buy
- Analyst Count
- REKR 0
- CABA 8
- Target Price
- REKR N/A
- CABA $26.13
- AVG Volume (30 Days)
- REKR 3.7M
- CABA 771.7K
- Earning Date
- REKR 03-31-2025
- CABA 03-31-2025
- Dividend Yield
- REKR N/A
- CABA N/A
- EPS Growth
- REKR N/A
- CABA N/A
- EPS
- REKR N/A
- CABA N/A
- Revenue
- REKR $43,817,000.00
- CABA N/A
- Revenue This Year
- REKR $33.40
- CABA N/A
- Revenue Next Year
- REKR $41.09
- CABA N/A
- P/E Ratio
- REKR N/A
- CABA N/A
- Revenue Growth
- REKR 44.46
- CABA N/A
- 52 Week Low
- REKR $0.78
- CABA $1.36
- 52 Week High
- REKR $2.67
- CABA $19.04
- Technical
- Relative Strength Index (RSI)
- REKR 34.15
- CABA 29.81
- Support Level
- REKR $0.99
- CABA $1.45
- Resistance Level
- REKR $1.18
- CABA $1.85
- Average True Range (ATR)
- REKR 0.09
- CABA 0.14
- MACD
- REKR 0.01
- CABA -0.01
- Stochastic Oscillator
- REKR 13.98
- CABA 4.65
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which the majority of its revenue comes from the United States.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.